A diarrhoeal-associated gut dysbiosis in cancer and inflammatory bowel disease patients is further impacted by Clostridioides difficile infection.
In this study, we used shotgun metagenomic sequencing and GC/MS metabolomics to compare the microbiota profiles and metabolite levels of hospitalized cancer patients with healthcare-associated diarrhea, patients with IBD, and healthy controls. Our data define a role of CDI in modulating low diversity dysbiosis.